Keywords: Celgene, Abraxane, NSCLC, Genentech, Roche, Actemra, Rheumatoid arthritis, USA, FDA

FDA Approves Abraxane for NSCLC and expands indication for Actemra

Article | 15 October 2012

Print This

The US Food and Drug Administration on Friday approved biotech firm Celgene’s (Nasdaq: CELG) Abraxane (paclitaxel protein-bound particles ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in